Search research articles
Contact Us
Filters
Showing results (491-500 of 688) with videos related to
Page
of 69
Sort By:
Heart Rhythm
|
February 6, 2017
The burden of proof: The current state of atrial fibrillation prevention and treatment trials
Rosita Zakeri, David R Van Wagoner, Hugh Calkins, et al.
Diabetes Care
|
January 21, 2022
Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes According to Baseline HbA1c and Insulin Use: An Analysis From the FIDELIO-DKD Study
Peter Rossing, Ellen Burgess, Rajiv Agarwal, et al.
Journal of the American College of Cardiology
|
October 1, 2024
Time to Significant Benefit of Finerenone in Patients With Heart Failure
Muthiah Vaduganathan, Brian L Claggett, Akshay S Desai, et al.
Circulation. Heart Failure
|
June 22, 2019
Utility of the Cardiovascular Physical Examination and Impact of Spironolactone in Heart Failure With Preserved Ejection Fraction
Senthil Selvaraj, Brian Claggett, Sanjiv J Shah, et al.
Blood Pressure
|
June 24, 2008
Predictors of blood pressure response to intensified and fixed combination treatment of hypertension: the ACCOMPLISH study
Sverre E Kjeldsen, Kenneth A Jamerson, George L Bakris, et al.
European Journal of Heart Failure
|
February 14, 2015
Rationale and design of MinerAlocorticoid Receptor antagonist Tolerability Study-Heart Failure (ARTS-HF): a randomized study of finerenone vs. eplerenone in patients who have worsening chronic heart failure with diabetes and/or chronic kidney disease
Bertram Pitt, Stefan D Anker, Michael Böhm, et al.
Clinical Kidney Journal
|
April 23, 2024
Validation of the Klinrisk chronic kidney disease progression model in the FIDELITY population
Navdeep Tangri, Thomas Ferguson, Silvia J Leon, et al.
Diabetes, Obesity & Metabolism
|
April 24, 2026
Outcomes With Finerenone by Baseline Treatment Goals in Type 2 Diabetes and Chronic Kidney Disease: A FIDELITY Analysis
João Sérgio Neves, Ana Rita Leite, Francisco Vasques-Nóvoa, et al.
JAMA
|
July 12, 2012
Effect of adenosine-regulating agent acadesine on morbidity and mortality associated with coronary artery bypass grafting: the RED-CABG randomized controlled trial
Mark F Newman, T Bruce Ferguson, Jennifer A White, et al.
JACC. Heart Failure
|
January 5, 2019
Efficacy and Safety of Spironolactone in Patients With HFpEF and Chronic Kidney Disease
Iris E Beldhuis, Peder L Myhre, Brian Claggett, et al.
Page
of 69
Search research articles
Search
Showing results (491-500 of 688) with videos related to
Sort By:
Page
of 69
Heart Rhythm
|
February 6, 2017
The burden of proof: The current state of atrial fibrillation prevention and treatment trials
Rosita Zakeri, David R Van Wagoner, Hugh Calkins, et al.
Diabetes Care
|
January 21, 2022
Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes According to Baseline HbA1c and Insulin Use: An Analysis From the FIDELIO-DKD Study
Peter Rossing, Ellen Burgess, Rajiv Agarwal, et al.
Journal of the American College of Cardiology
|
October 1, 2024
Time to Significant Benefit of Finerenone in Patients With Heart Failure
Muthiah Vaduganathan, Brian L Claggett, Akshay S Desai, et al.
Circulation. Heart Failure
|
June 22, 2019
Utility of the Cardiovascular Physical Examination and Impact of Spironolactone in Heart Failure With Preserved Ejection Fraction
Senthil Selvaraj, Brian Claggett, Sanjiv J Shah, et al.
Blood Pressure
|
June 24, 2008
Predictors of blood pressure response to intensified and fixed combination treatment of hypertension: the ACCOMPLISH study
Sverre E Kjeldsen, Kenneth A Jamerson, George L Bakris, et al.
European Journal of Heart Failure
|
February 14, 2015
Rationale and design of MinerAlocorticoid Receptor antagonist Tolerability Study-Heart Failure (ARTS-HF): a randomized study of finerenone vs. eplerenone in patients who have worsening chronic heart failure with diabetes and/or chronic kidney disease
Bertram Pitt, Stefan D Anker, Michael Böhm, et al.
Clinical Kidney Journal
|
April 23, 2024
Validation of the Klinrisk chronic kidney disease progression model in the FIDELITY population
Navdeep Tangri, Thomas Ferguson, Silvia J Leon, et al.
Diabetes, Obesity & Metabolism
|
April 24, 2026
Outcomes With Finerenone by Baseline Treatment Goals in Type 2 Diabetes and Chronic Kidney Disease: A FIDELITY Analysis
João Sérgio Neves, Ana Rita Leite, Francisco Vasques-Nóvoa, et al.
JAMA
|
July 12, 2012
Effect of adenosine-regulating agent acadesine on morbidity and mortality associated with coronary artery bypass grafting: the RED-CABG randomized controlled trial
Mark F Newman, T Bruce Ferguson, Jennifer A White, et al.
JACC. Heart Failure
|
January 5, 2019
Efficacy and Safety of Spironolactone in Patients With HFpEF and Chronic Kidney Disease
Iris E Beldhuis, Peder L Myhre, Brian Claggett, et al.
Page
of 69